Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 2, 2021

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2025

Conditions
Recurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian Carcinoma
Interventions
DRUG

Abemaciclib

Given PO

PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood

DRUG

Olaparib

Given PO

Trial Locations (23)

10032

SUSPENDED

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

19107

RECRUITING

Thomas Jefferson University Hospital, Philadelphia

22908

RECRUITING

University of Virginia Cancer Center, Charlottesville

27157

RECRUITING

Wake Forest University Health Sciences, Winston-Salem

33136

ACTIVE_NOT_RECRUITING

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

33146

ACTIVE_NOT_RECRUITING

UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables

33324

ACTIVE_NOT_RECRUITING

UM Sylvester Comprehensive Cancer Center at Plantation, Plantation

33442

ACTIVE_NOT_RECRUITING

UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach

37232

RECRUITING

Vanderbilt University/Ingram Cancer Center, Nashville

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

60611

ACTIVE_NOT_RECRUITING

Northwestern University, Chicago

64064

SUSPENDED

University of Kansas Cancer Center - Lee's Summit, Lee's Summit

64116

SUSPENDED

University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City

64154

SUSPENDED

University of Kansas Cancer Center - North, Kansas City

66160

SUSPENDED

University of Kansas Cancer Center, Kansas City

66205

RECRUITING

University of Kansas Clinical Research Center, Fairway

SUSPENDED

University of Kansas Hospital-Westwood Cancer Center, Westwood

66210

SUSPENDED

University of Kansas Cancer Center-Overland Park, Overland Park

66211

SUSPENDED

University of Kansas Hospital-Indian Creek Campus, Overland Park

73104

RECRUITING

University of Oklahoma Health Sciences Center, Oklahoma City

85054

ACTIVE_NOT_RECRUITING

Mayo Clinic Hospital in Arizona, Phoenix

32224-9980

RECRUITING

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT04633239 - Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter